Novo Nordisk Raises Annual Outlook Amid Strong Demand for Wegovy and Ozempic
Novo Nordisk has upgraded its full-year financial guidance, driven by sustained high demand for its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic. The Danish pharmaceutical giant's revised outlook reflects a robust market position in the metabolic health sector. The company now expects annual sales and operating profit to either decline slightly by 2% or increase by as much as [percentage not fully provided in snippet], signaling confidence in its production capabilities and market penetration despite previous supply constraints.
Tickers: $NVO
Topics: earnings guidance pharmaceuticals weight-loss drugs
Read the full article at Seeking Alpha
Part of the story Loar Holdings Raises 2026 Sales Outlook and Provides Strong 2027 Guidance (7 articles)